Merck's (MRK.US) oral anti-HIV drug applies for market approval in China

Smart Finance APP reported that on August 5, the official website of the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration announced that the marketing application for Merck & Co. (MRK.US)'s doravirine/islatravir (DOR/ISL) tablets has been accepted. According to the CDE website, this product was previously included in the priority review list, and the proposed indication is: as a complete two-drug regimen for the treatment of adult HIV-1 infection, suitable for patients who are currently receiving a stable antiretroviral regimen and have achieved virological suppression (HIV-1 RNA